Department of Drug Discovery for Lung Diseases, Graduate School of Medicine, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan.
Watarase Research Center, Kyorin Pharmaceutical Co. Ltd., Shimotsuga-gun, Tochigi, Japan.
Respir Res. 2021 Nov 4;22(1):284. doi: 10.1186/s12931-021-01877-8.
Somatic cells differentiated from patient-specific human induced pluripotent stem cells (iPSCs) could be a useful tool in human cell-based disease research. Hermansky-Pudlak syndrome (HPS) is an autosomal recessive genetic disorder characterized by oculocutaneous albinism and a platelet dysfunction. HPS patients often suffer from lethal HPS associated interstitial pneumonia (HPSIP). Lung transplantation has been the only treatment for HPSIP. Lysosome-related organelles are impaired in HPS, thereby disrupting alveolar type 2 (AT2) cells with lamellar bodies. HPSIP lungs are characterized by enlarged lamellar bodies. Despite species differences between human and mouse in HPSIP, most studies have been conducted in mice since culturing human AT2 cells is difficult.
We generated patient-specific iPSCs from patient-derived fibroblasts with the most common bi-allelic variant, c.1472_1487dup16, in HPS1 for modeling severe phenotypes of HPSIP. We then corrected the variant of patient-specific iPSCs using CRISPR-based microhomology-mediated end joining to obtain isogenic controls. The iPSCs were then differentiated into lung epithelial cells using two different lung organoid models, lung bud organoids (LBOs) and alveolar organoids (AOs), and explored the phenotypes contributing to the pathogenesis of HPSIP using transcriptomic and proteomic analyses.
The LBOs derived from patient-specific iPSCs successfully recapitulated the abnormalities in morphology and size. Proteomic analysis of AOs involving iPSC-derived AT2 cells and primary lung fibroblasts revealed mitochondrial dysfunction in HPS1 patient-specific alveolar epithelial cells. Further, giant lamellar bodies were recapitulated in patient-specific AT2 cells.
The HPS1 patient-specific iPSCs and their gene-corrected counterparts generated in this study could be a new research tool for understanding the pathogenesis of HPSIP caused by HPS1 deficiency in humans.
源自患者特异性人诱导多能干细胞(iPSC)的体细胞可以成为人类基于细胞的疾病研究的有用工具。Hermansky-Pudlak 综合征(HPS)是一种常染色体隐性遗传疾病,其特征为眼皮肤白化病和血小板功能障碍。HPS 患者常患有致命的 HPS 相关间质性肺炎(HPSIP)。肺移植一直是 HPSIP 的唯一治疗方法。HPS 中溶酶体相关细胞器受损,从而破坏具有板层小体的肺泡 2 型(AT2)细胞。HPSIP 肺的特征为板层小体增大。尽管 HPSIP 中人类和小鼠之间存在种间差异,但由于培养人类 AT2 细胞较为困难,大多数研究都在小鼠中进行。
我们从 HPS1 中最常见的双等位基因变体 c.1472_1487dup16 的患者衍生成纤维细胞中生成了患者特异性 iPSC,以模拟 HPSIP 的严重表型。然后,我们使用基于 CRISPR 的微同源介导末端连接来纠正患者特异性 iPSC 的变体,以获得同基因对照。然后,我们使用两种不同的肺类器官模型(肺芽类器官(LBO)和肺泡类器官(AO))将 iPSC 分化为肺上皮细胞,并使用转录组学和蛋白质组学分析探索导致 HPSIP 发病机制的表型。
从患者特异性 iPSC 中衍生的 LBO 成功地再现了形态和大小的异常。涉及 iPSC 衍生的 AT2 细胞和原代肺成纤维细胞的 AO 的蛋白质组学分析显示 HPS1 患者特异性肺泡上皮细胞中线粒体功能障碍。此外,在患者特异性 AT2 细胞中再现了巨大的板层小体。
本研究中生成的 HPS1 患者特异性 iPSC 及其基因校正对应物可以成为理解 HPS1 缺乏引起的 HPSIP 发病机制的新研究工具。